Cdk5 deregulation in the pathogenesis of Alzheimer's disease.

The aberrant metabolism of tau and β-amyloid precursor protein (APP) has key roles in the neurodegenerative processes that contribute to the etiology of Alzheimer's disease (AD). These pathological characteristics of AD have recently been linked to the deregulation of cyclin-dependent kinase 5 (cdk5). The finding that the inducible expression of p25, which is the neurotoxic activator of cdk5, triggers progressive neurodegeneration and neurofibrillary tangle formation in mice provides compelling evidence that p25–cdk5 is one of the crucial pathways that can lead to AD pathophysiology. Furthermore, a role for cdk5 in modulating APP processing and β-amyloid generation is emerging. Therefore, as one of the molecular links between APP and tau, cdk5 might be a valuable target for therapeutic intervention in AD and other neurodegenerative diseases.

[1]  Hiroshi Takahashi,et al.  Involvement of cyclin dependent kinase5 activator p25 on tau phosphorylation in mouse brain , 2001, Neuroscience Letters.

[2]  L. Tsai,et al.  Colocalization and Fluorescence Resonance Energy Transfer between cdk5 and AT8 Suggests a Close Association in Pre‐Neurofibrillary Tangles and Neurofibrillary Tangles , 2002, Journal of neuropathology and experimental neurology.

[3]  F. Liu,et al.  Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5 , 2003, FEBS letters.

[4]  J. Julien,et al.  Deregulation of Cdk5 in a Mouse Model of ALS Toxicity Alleviated by Perikaryal Neurofilament Inclusions , 2001, Neuron.

[5]  Junmin Peng,et al.  Cdk5-Mediated Inhibition of the Protective Effects of Transcription Factor MEF2 in Neurotoxicity-Induced Apoptosis , 2003, Neuron.

[6]  Tony Hunter,et al.  Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration , 2003, Nature.

[7]  R. Booher,et al.  Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25‐transgenic mice , 2002, The Journal of comparative neurology.

[8]  L. Tsai,et al.  Neurotoxicity induces cleavage of p35 to p25 by calpain , 2000, Nature.

[9]  G. Pigino,et al.  A novel CDK5‐dependent pathway for regulating GSK3 activity and kinesin‐driven motility in neurons , 2004, The EMBO journal.

[10]  J. Hardy,et al.  The relationship between amyloid and tau , 2003, Journal of Molecular Neuroscience.

[11]  Kazuyuki Takata,et al.  Cdk5 Is a Key Factor in Tau Aggregation and Tangle Formation In Vivo , 2003, Neuron.

[12]  M. Mullan,et al.  p35/Cdk5 pathway mediates soluble amyloid‐β peptide‐induced tau phosphorylation in vitro , 2002, Journal of neuroscience research.

[13]  J. Radulovic,et al.  Cyclin-Dependent Kinase 5 Is Required for Associative Learning , 2002, The Journal of Neuroscience.

[14]  L. Tsai,et al.  Structure and Regulation of the CDK5-p25nck5a Complex , 2001 .

[15]  R. Maccioni,et al.  Inhibition of tau phosphorylating protein kinase cdk5 prevents β‐amyloid‐induced neuronal death , 1999, FEBS letters.

[16]  Wei Li,et al.  Interaction of Neuronal Cdc2-like Protein Kinase with Microtubule-associated Protein Tau* , 2000, The Journal of Biological Chemistry.

[17]  Y. Kirino,et al.  Phosphorylation-dependent Regulation of the Interaction of Amyloid Precursor Protein with Fe65 Affects the Production of β-Amyloid* , 2001, The Journal of Biological Chemistry.

[18]  A. Kulkarni,et al.  Regulation of NMDA receptors by cyclin-dependent kinase-5 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Bibb,et al.  Developmental Regulation of the Proteolysis of the p35 Cyclin-Dependent Kinase 5 Activator by Phosphorylation , 2003, The Journal of Neuroscience.

[20]  Li-Huei Tsai,et al.  NUDEL Is a Novel Cdk5 Substrate that Associates with LIS1 and Cytoplasmic Dynein , 2000, Neuron.

[21]  L. Nicholson,et al.  Phosphorylation-induced structural changes in the amyloid precursor protein cytoplasmic tail detected by NMR. , 2001, Journal of molecular biology.

[22]  K. Tomizawa,et al.  An Isoform of the Neuronal Cyclin-dependent Kinase 5 (Cdk5) Activator (*) , 1995, The Journal of Biological Chemistry.

[23]  B. Lu,et al.  PAR-1 Kinase Plays an Initiator Role in a Temporally Ordered Phosphorylation Process that Confers Tau Toxicity in Drosophila , 2004, Cell.

[24]  H. Geerts,et al.  Coexpression of Human cdk5 and Its Activator p35 with Human Protein Tau in Neurons in Brain of Triple Transgenic Mice , 2001, Neurobiology of Disease.

[25]  I. Vincent,et al.  Mitotic activation: a convergent mechanism for a cohort of neurodegenerative diseases , 2000, Neurobiology of Aging.

[26]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[27]  K. Lau,et al.  Cyclin-Dependent Kinase-5/p35 Phosphorylates Presenilin 1 to Regulate Carboxy-Terminal Fragment Stability , 2002, Molecular and Cellular Neuroscience.

[28]  P. Greengard,et al.  Neuron‐Specific Phosphorylation of Alzheimer's β‐Amyloid Precursor Protein by Cyclin‐Dependent Kinase 5 , 2000, Journal of neurochemistry.

[29]  I. Grundke‐Iqbal,et al.  Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5 , 1997, Molecular and Cellular Biochemistry.

[30]  G. Schellenberg,et al.  A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L) , 1999, Brain : a journal of neurology.

[31]  L. Tsai,et al.  Cyclin-Dependent Kinase 5 Phosphorylates the N-Terminal Domain of the Postsynaptic Density Protein PSD-95 in Neurons , 2004, The Journal of Neuroscience.

[32]  F. Plattner,et al.  Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression , 2003, The European journal of neuroscience.

[33]  R. Aebersold,et al.  A brain-specific activator of cyclin-dependent kinase 5 , 1994, Nature.

[34]  D. Geschwind.  Tau Phosphorylation, Tangles, and Neurodegeneration The Chicken or the Egg? , 2003, Neuron.

[35]  M. Larsen,et al.  Cdk5 is essential for synaptic vesicle endocytosis , 2003, Nature Cell Biology.

[36]  L. Tsai,et al.  Calpain-mediated Cleavage of the Cyclin-dependent Kinase-5 Activator p39 to p29* , 2002, The Journal of Biological Chemistry.

[37]  R. Nixon,et al.  Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease , 1997, Brain Research.

[38]  Jerry H. Wang,et al.  Cdk5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors , 2003, Nature Neuroscience.

[39]  David S. Park,et al.  Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Clark,et al.  Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain , 1999, Neuroscience Research.

[41]  K. Mikoshiba,et al.  Cophosphorylation of amphiphysin I and dynamin I by Cdk5 regulates clathrin-mediated endocytosis of synaptic vesicles , 2003, The Journal of cell biology.

[42]  P. Davies,et al.  Deregulation of cdk5, Hyperphosphorylation, and Cytoskeletal Pathology in the Niemann–Pick Type C Murine Model , 2002, The Journal of Neuroscience.

[43]  L. Tsai,et al.  p35 and p39 Are Essential for Cyclin-Dependent Kinase 5 Function during Neurodevelopment , 2001, The Journal of Neuroscience.

[44]  R. D. Williams,et al.  Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[45]  L. Tsai,et al.  The Cyclin-Dependent Kinase 5 Activators p35 and p39 Interact with the α-Subunit of Ca2+/Calmodulin-Dependent Protein Kinase II and α-Actinin-1 in a Calcium-Dependent Manner , 2002, The Journal of Neuroscience.

[46]  L. Tsai,et al.  A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains , 2002, FEBS letters.

[47]  L. Tsai,et al.  APP processing is regulated by cytoplasmic phosphorylation , 2003, The Journal of cell biology.

[48]  D. Geschwind,et al.  Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila , 2002, Neuron.

[49]  L. Tsai,et al.  p35, the Neuronal-specific Activator of Cyclin-dependent Kinase 5 (Cdk5) Is Degraded by the Ubiquitin-Proteasome Pathway* , 1998, The Journal of Biological Chemistry.

[50]  H. Soininen,et al.  Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (cdk5), on the proteolysis of p35. , 2002, Brain research. Molecular brain research.

[51]  M. D'Andrea.  Evidence linking neuronal cell death to autoimmunity in Alzheimer’s disease , 2003, Brain Research.

[52]  L. Tsai,et al.  p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5 , 1994, Nature.

[53]  Li-Huei Tsai,et al.  Aberrant Cdk5 Activation by p25 Triggers Pathological Events Leading to Neurodegeneration and Neurofibrillary Tangles , 2003, Neuron.

[54]  R. DePinho,et al.  Decreased Cyclin-Dependent Kinase 5 (cdk5) Activity Is Accompanied by Redistribution of cdk5 and Cytoskeletal Proteins and Increased Cytoskeletal Protein Phosphorylation in p35 Null Mice , 2003, The Journal of Neuroscience.

[55]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[56]  T. Curran,et al.  Cyclin-Dependent Kinase 5 Phosphorylates Disabled 1 Independently of Reelin Signaling , 2002, The Journal of Neuroscience.

[57]  A. Bush,et al.  Metals and neuroscience. , 2000, Current opinion in chemical biology.

[58]  K. Wang,et al.  Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells. , 2000, Biochemical and biophysical research communications.

[59]  A. Delacourte,et al.  Increase of cdk5 is related to neurofibrillary pathology in progressive supranuclear palsy , 2002, Neurology.

[60]  Jochen H Weishaupt,et al.  Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction , 2003, Molecular and Cellular Neuroscience.

[61]  L. Tsai,et al.  Mice Lacking p35, a Neuronal Specific Activator of Cdk5, Display Cortical Lamination Defects, Seizures, and Adult Lethality , 1997, Neuron.

[62]  Taro Saito,et al.  Truncation of CDK5 Activator p35 Induces Intensive Phosphorylation of Ser202/Thr205 of Human Tau* , 2002, The Journal of Biological Chemistry.

[63]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[64]  B. Wolozin,et al.  The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. , 2006, CNS drug reviews.

[65]  K. Ishiguro,et al.  Calpain-dependent Proteolytic Cleavage of the p35 Cyclin-dependent Kinase 5 Activator to p25* , 2000, The Journal of Biological Chemistry.

[66]  D. Flaherty,et al.  Phosphorylation of human tau protein by microtubule‐associated kinases: GSK3β and cdk5 are key participants , 2000, Journal of neuroscience research.

[67]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[68]  A. Wynshaw-Boris,et al.  A LIS1/NUDEL/Cytoplasmic Dynein Heavy Chain Complex in the Developing and Adult Nervous System , 2000, Neuron.

[69]  F. Liu,et al.  Divergent roles of GSK3 and CDK5 in APP processing. , 2003, Biochemical and biophysical research communications.

[70]  A. Kulkarni,et al.  Tau Phosphorylation by Cyclin-dependent Kinase 5/p39 during Brain Development Reduces Its Affinity for Microtubules* , 2003, The Journal of Biological Chemistry.

[71]  R. Maccioni,et al.  AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. , 2002, Journal of Alzheimer's disease : JAD.